Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29301436 | 0.78 | MAPT (0.49) | GAAMAPT | |
| SCHEMBL10233313 | 0.78 | GAA (0.49) | GAAMAPT | |
| SCHEMBL30681474 | 0.76 | AR (0.45) | GAAMAPT | |
| SCHEMBL28849076 | 0.74 | GAA (0.45) | GAAMAPT | |
| SCHEMBL27813563 | 0.74 | GAA (0.55) | GAAMAPT | |
| SCHEMBL25268618 | 0.73 | HDAC4 (0.35) | SLC6A9GPR65HDAC4 | |
| SCHEMBL27894459 | 0.72 | GAA (0.56) | GAAMAPT | |
| SCHEMBL29153655 | 0.71 | NNMT (0.39) | GAAMAPTITGB1ITGA2 | |
| SCHEMBL29153653 | 0.71 | NNMT (0.39) | GAAMAPTITGB1ITGA2 | |
| SCHEMBL2608565 | 0.71 | GAA (0.51) | GAAMAPTITGB1ITGA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | GAA 1848/4885MAPT 32/4885ITGB1 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.